Danish pharmaceutical giant Novo Nordisk, Europe’s most valuable company, said Wednesday its net profit soared by 51 percent last year, driven by sales of its popular diabetes and obesity drugs.
Novo Nordisk reported a net profit of 83.7 billion kroner ($12.1 billion), which was higher than the 82.07 billion kroner forecast by analysts surveyed by financial data firm FactSet, reports BSS.
